Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow (Nasdaq: HROW) has announced an agreement to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company specializing in non-opioid, non-IV sedation therapies. The acquisition's centerpiece is MELT-300, a patented sublingual formulation combining midazolam and ketamine that showed positive Phase 3 results in November 2024.
MELT-300 demonstrated statistical superiority over both sublingual midazolam and placebo in the LOUISE study. Harrow plans to submit an NDA in 2027, targeting a 2028 commercial launch. The company will leverage its experience with MKO Melt®, which has been used in over 500,000 cataract surgeries, to enter the multi-billion-dollar U.S. procedural sedation market.
Harrow (NASDAQ: HROW) has announced the launch of Harrow Access for All (HAFA), a comprehensive market access program expanding across their ophthalmic portfolio. Building on the success of VEVYE Access for All (VAFA), which drove a 66% growth in VEVYE prescriptions in Q2 2025, HAFA will provide affordable access to Harrow's branded, generic, and compounded eye medications.
The program will roll out in three phases starting Q4 2025, with eligible commercially insured patients paying as little as $0 and a maximum of $59 out-of-pocket. HAFA will be accessible through the HarrowAccess.com portal, offering streamlined prescribing, protocol decision trees, and simplified prior authorizations for healthcare providers.
Harrow (NASDAQ: HROW), a leading North American ophthalmic disease management solutions provider, has announced its upcoming Investor & Analyst Day scheduled for September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will feature comprehensive presentations from the company's leadership team and renowned physician key opinion leaders.
The agenda includes presentations on Harrow's commercial portfolio, pipeline products, and long-term vision. Notable speakers include four distinguished medical experts: Dr. Paul Karpecki (dry eye specialist), Dr. Raj Patel (retina specialist), Dr. Seenu Hariprasad (vitreoretinal expert), and Dr. Maggie Jeffries (ophthalmic anesthesia specialist). Topics will cover MELT-300 development, VEVYE, TRIESENCE expansion, BYQLOVI, and ImprimisRx operations.
The event will be accessible via live webcast for public viewers, while in-person attendance is limited to invited research analysts and institutional investors.
Harrow (NASDAQ: HROW), a leading North American ophthalmic disease management solutions provider, has announced the pricing of $250.0 million senior unsecured notes due 2030. The notes will bear an interest rate of 8.625%, payable semi-annually starting March 15, 2026.
The proceeds will be used to repay multiple existing debts, including a $107.5 million Oaktree facility, $75.0 million of 8.625% Senior Notes (HROWL), and $40.25 million of 11.875% Senior Notes (HROWM). The offering, priced at 100% of principal amount, is expected to close on September 12, 2025, and is available only to qualified institutional buyers under Rule 144A.
Harrow (Nasdaq: HROW), a leading ophthalmic disease management solutions provider, has launched a private offering of $250.0 million senior unsecured notes due 2030. The company also secured a commitment for a new $40 million revolving credit facility with Fifth Third Bank.
The proceeds will be used to repay a $107.5 million Oaktree facility, redeem $75.0 million of 8.625% Senior Notes (HROWL) and $40.25 million of 11.875% Senior Notes (HROWM). Both HROWL and HROWM will be delisted from Nasdaq following redemption. The 2030 Notes will be guaranteed by Harrow's existing and future wholly-owned domestic restricted subsidiaries.
Harrow (NASDAQ: HROW), a leading ophthalmic solutions provider, reported strong Q2 2025 financial results with total revenues of $63.7 million, up 30% year-over-year. The company achieved GAAP net income of $5.0 million and Adjusted EBITDA of $17.0 million.
Key highlights include VEVYE®'s 66% sequential prescription growth with 50,000 new prescriptions and a 3% market share gain. The company secured exclusive U.S. rights to Samsung Bioepis' ophthalmology biosimilars (BYOOVIZ® and OPUVIZ™) and acquired BYQLOVI™ for post-operative inflammation treatment. Harrow maintains its forecast of over $280 million in revenue for 2025, with strong cash position of $53.0 million.
The company expanded its VEVYE® Access for All program through a strategic alliance with Apollo Care, adding 500+ pharmacies nationwide.Harrow (NASDAQ: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Conference on August 13, 2025.
CEO Mark L. Baum and CFO Andrew Boll will participate in a fireside chat at 8:30 a.m. ET. Additionally, Baum will join a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1:00 p.m. ET. Both sessions will be available via webcast on the company's website, with replays accessible for 90 days after the event.
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 11, 2025, after market close.
The company will release its quarterly Letter to Stockholders on its website and host a conference call with a live webcast on August 12, 2025, at 8:00 a.m. Eastern Time. Investors can access the webcast through Harrow's website, and telephone participants must register in advance to receive dial-in details.
Harrow (NASDAQ:HROW) has secured exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio through a definitive agreement. The portfolio includes BYOOVIZ® (ranibizumab-nuna), a LUCENTIS biosimilar, and OPUVIZ™ (aflibercept-yszy), an EYLEA biosimilar, for treating retinal diseases.
The transition from current commercialization partner Biogen is expected to complete by end of 2025. This strategic acquisition targets a $9 billion U.S. market opportunity in retinal disease treatment, with current anti-VEGF therapies accounting for over $4.2 billion in annual Medicare Part B spending. The deal positions Harrow as a leading full-spectrum ophthalmic pharmaceuticals provider, aiming to improve treatment accessibility and affordability.
Samsung Bioepis has partnered with Harrow (NASDAQ: HROW) for the commercialization of two ophthalmology biosimilars in the United States. The agreement covers BYOOVIZ® (ranibizumab-nuna), the first FDA-approved ophthalmology biosimilar, and OPUVIZ™ (aflibercept-yszy).
The commercial license will become effective after Biogen's rights transition back to Samsung Bioepis by the end of 2025. BYOOVIZ, approved in September 2021, has been available since June 2022, while OPUVIZ received FDA approval in May 2024. Both biosimilars target conditions including Wet Age-Related Macular Degeneration, Macular Edema, and other eye disorders.